Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Isoetharine + phenylephrine** is a historical fixed-dose inhaled bronchodilator combination marketed as **Bronkosol**. Isoetharine is a relatively selective short-acting beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, while phenylephrine is an alpha-1 adrenergic receptor agonist. In controlled studies in asthma and reversible bronchospasm, the combination produced bronchodilation, although phenylephrine alone did not produce bronchodilation and its addition to isoetharine showed no clear incremental pulmonary benefit. The product is discontinued. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/323326/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoetharine + phenylephrine.